High-risk metastatic gestational trophoblastic disease

Obstet Gynecol. 1985 Apr;65(4):550-6.

Abstract

The clinical course of 61 patients with high-risk metastatic gestational trophoblastic disease was reviewed. Currently, 34 patients (56%) are alive and in complete remission. The survival rate after full-term pregnancy was significantly worse than after any other type of antecedent pregnancy. Analyzing survival by individual high-risk criteria revealed significantly improved survival for those patients with elevated beta-human chorionic gonadotropin titer alone when compared with all other high-risk criteria. Fifty-eight percent of patients (14 of 24) primarily treated with alternating-sequential therapy consisting of methotrexate and actinomycin-D experienced a complete remission. Of those patients primarily treated with methotrexate, actinomycin-D, and cyclophosphamide, 63% (20 of 32) achieved a complete remission. Treatment with second-line chemotherapy was largely unsuccessful. Aggressive early treatment is warranted in this group of patients, using multiagent chemotherapy. A search for newer more effective regimens should continue.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chorionic Gonadotropin / blood
  • Chorionic Gonadotropin, beta Subunit, Human
  • Combined Modality Therapy
  • Dactinomycin / administration & dosage
  • Female
  • Humans
  • Liver Neoplasms / secondary
  • Lung Neoplasms / secondary
  • Methotrexate / administration & dosage
  • Neoplasm Metastasis
  • Peptide Fragments / blood
  • Pregnancy
  • Retrospective Studies
  • Risk
  • Trophoblastic Neoplasms* / drug therapy
  • Trophoblastic Neoplasms* / mortality
  • Trophoblastic Neoplasms* / physiopathology
  • Uterine Neoplasms* / drug therapy
  • Uterine Neoplasms* / mortality
  • Uterine Neoplasms* / physiopathology

Substances

  • Chorionic Gonadotropin
  • Chorionic Gonadotropin, beta Subunit, Human
  • Peptide Fragments
  • Dactinomycin
  • Methotrexate